March 24th 2023
Survey respondents indicated a lack of comfort around recommending psilocybin therapy to patients.
February 27th 2023
February 20th 2023
NDA for Zuranolone for Depression Accepted by FDAFebruary 7th 2023
Zuranolone, a fast-acting neuroactive steroid that can take effect in 14 days, has been assigned a PDUFA action date of Aug. 5, 2023 by the FDA. It can be used to treat patients with major depressive disorder and postpartum depression.
Cardiovascular Disease Risk Not Significantly Increased ADHD MedicationsJanuary 17th 2023
A recent study found that the risk of cardiovascular diseases was not significantly greater in patients taking medications for attention-deficit/hyperactivity disorder (ADHD), but investigators were not able to rule out a mild risk increase.
Coumadin No Worse for Mental Function Than Pradaxa, When Well AdministeredDecember 20th 2022
Pradaxa (dabigatran) and Coumadin (warfarin) came out even in this randomized study. The Brazilian researchers who conducted the study said one explanation for the result is that use of Coumadin was exceptionally well managed because the patients were enrolled a study.